How Biosergen AB Is Revolutionizing Antifungal Therapy on the Global Stage
Discover how Biosergen AB is reshaping antifungal therapy with cutting‑edge biopharma research, global reach, and transparent Swedish‑exchange trading.
2 minutes to read
BIOSERGEN
Flerie AB Acquires Biosergen AB: $54.7 M Merger Powers Antifungal Innovation and Capital Growth
Discover how Biosergen AB’s €54.7 M merger with Flerie AB will boost its antifungal pipeline, unlock new funding, and reshape biotech consolidation in Sweden.
2 minutes to read
Biogen AB Fuels Antifungal Growth: 54.7M SEK Valuation, 40M SEK Capital for BSG005
Biopharma breakthrough: Biosergen AB’s merger with Flerie and 40 M SEK funding boost accelerate BSG005 antifungal development, raising confidence and market reach.
2 minutes to read